ESTRO 2024 - Abstract Book

S1292

Clinical - Head & neck

ESTRO 2024

Conclusion:

NRAS mutated gene status provided a trend for better OS in patients treated with CIRT for HNMM. However, the small size, reduced number of events and heterogeneity of the patients’ sample as well as the short follow -up, make difficult a clear interpretation of the data. Further studies (preferably multicentric and considering whole gene profile) are warranted to better define the potential prognostic role on clinical outcomes after CIRT.

Keywords: Mucosal Melanoma, CIRT, NRAS mutational status

1421

Proffered Paper

Radiation vs Transoral Robotic Surgery for Oropharyngeal Cancer: Final Results of the ORATOR Trial

David A Palma 1 , Julie Theurer 2 , Nancy Read 3 , Eric Tran 4 , Kevin Fung 5 , John R. de Almeida 6 , Andrew Bayley 7 , David P. Goldstein 6 , Michael Hier 8 , Keith Richardson 8 , Alex Mlynarek 8 , Suren Krishnan 9 , Hien Le 10 , S. Danielle MacNeil 5 , Eric Winquist 11 , Sara Kuruvilla 11 , Andrew Warner 3 , Sylvia Mitchell 3 , Jeff Chen 3 , Martin Corsten 12 , Stephanie Johnson Obaseki 12 , Michael Odell 12 , Christina Parker 13 , Keith Kwan 14 , Anthony C Nichols 15 1 Western University, Radiation Oncology, London, Canada. 2 Western University, School of Communication Sciences and Disorders, London, Canada. 3 London Health Sciences Centre, Radiation Oncology, London, Canada. 4 University of British Columbia, Radiation Oncology, Vancouver, Canada. 5 Western University, Otolaryngology – Head and Neck Surgery, London, Canada. 6 University of Toronto, Otolaryngology – Head and Neck Surgery, Toronto, Canada. 7 Sunnybrook Health Sciences Centre, Radiation Oncology, Toronto, Canada. 8 McGill University, Otolaryngology – Head and Neck Surgery, Montreal, Canada. 9 Royal Adelaide Hospital, Otolaryngology – Head and Neck Surgery, Adelaide, Australia. 10 Royal Adelaide Hospital, Radiation Oncology, Adelaide, Australia. 11 London Health Sciences